Declared Dividend • May 16
Final dividend increased to ₹4.00 Dividend of ₹4.00 is 33% higher than last year. Ex-date: 29th May 2026 Payment date: 13th June 2026 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (4% earnings payout ratio) and cash flows (17% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 30% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • May 15
Full year 2026 earnings: EPS and revenues exceed analyst expectations Full year 2026 results: EPS: ₹84.36 (up from ₹70.57 in FY 2025). Revenue: ₹23.0b (up 19% from FY 2025). Net income: ₹6.41b (up 20% from FY 2025). Profit margin: 28% (in line with FY 2025). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 3.7%. Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • May 07
Caplin Point Laboratories Limited to Report Q4, 2026 Results on May 14, 2026 Caplin Point Laboratories Limited announced that they will report Q4, 2026 results on May 14, 2026 Board Change • Feb 10
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-executive Independent Director Susan Mathew was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 06
Third quarter 2026 earnings released: EPS: ₹21.56 (vs ₹18.28 in 3Q 2025) Third quarter 2026 results: EPS: ₹21.56 (up from ₹18.28 in 3Q 2025). Revenue: ₹5.76b (up 17% from 3Q 2025). Net income: ₹1.64b (up 18% from 3Q 2025). Profit margin: 28% (in line with 3Q 2025). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Jan 27
Caplin Point Laboratories Limited to Report Q3, 2026 Results on Feb 05, 2026 Caplin Point Laboratories Limited announced that they will report Q3, 2026 results on Feb 05, 2026 Reported Earnings • Nov 06
Second quarter 2026 earnings released: EPS: ₹20.32 (vs ₹17.22 in 2Q 2025) Second quarter 2026 results: EPS: ₹20.32 (up from ₹17.22 in 2Q 2025). Revenue: ₹5.64b (up 17% from 2Q 2025). Net income: ₹1.54b (up 18% from 2Q 2025). Profit margin: 27% (in line with 2Q 2025). Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Oct 29
Caplin Point Laboratories Limited to Report Q2, 2026 Results on Nov 05, 2025 Caplin Point Laboratories Limited announced that they will report Q2, 2026 results on Nov 05, 2025 Upcoming Dividend • Sep 05
Upcoming dividend of ₹3.00 per share Eligible shareholders must have bought the stock before 12 September 2025. Payment date: 21 October 2025. Payout ratio is a comfortable 8.5% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.8%). Declared Dividend • Aug 09
Dividend of ₹3.00 announced Shareholders will receive a dividend of ₹3.00. Ex-date: 12th September 2025 Payment date: 21st October 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (8% earnings payout ratio) and cash flows (19% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 17% over the next year, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Aug 08
First quarter 2026 earnings released: EPS: ₹20.10 (vs ₹16.32 in 1Q 2025) First quarter 2026 results: EPS: ₹20.10 (up from ₹16.32 in 1Q 2025). Revenue: ₹5.33b (up 16% from 1Q 2025). Net income: ₹1.53b (up 23% from 1Q 2025). Profit margin: 29% (up from 27% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Aug 07
Caplin Point Laboratories Limited, Annual General Meeting, Sep 22, 2025 Caplin Point Laboratories Limited, Annual General Meeting, Sep 22, 2025. Tillkännagivande • Jul 30
Caplin Point Laboratories Limited to Report Q1, 2026 Results on Aug 07, 2025 Caplin Point Laboratories Limited announced that they will report Q1, 2026 results on Aug 07, 2025 Declared Dividend • May 17
Final dividend of ₹3.00 announced Shareholders will receive a dividend of ₹3.00. Ex-date: 30th May 2025 Payment date: 14th June 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (4% earnings payout ratio) and cash flows (16% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 35% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • May 16
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: ₹70.57 (up from ₹60.20 in FY 2024). Revenue: ₹20.3b (up 20% from FY 2024). Net income: ₹5.36b (up 17% from FY 2024). Profit margin: 26% (in line with FY 2024). Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 2.1%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • May 10
Caplin Point Laboratories Limited to Report Fiscal Year 2025 Results on May 15, 2025 Caplin Point Laboratories Limited announced that they will report fiscal year 2025 results on May 15, 2025 Tillkännagivande • Apr 22
Caplin Point Laboratories Limited Announces Resignation of Thiagaraja Manikandan as Chief Transformation & Digital Officer, A Senior Management Personnel, Effective April 21, 2025 Caplin Point Laboratories Limited announced that Mr. Thiagaraja Manikandan, Chief Transformation & Digital Officer, a Senior Management Personnel (SMP) of the Company, has resigned with effect from the close of working hours of April 21, 2025. Valuation Update With 7 Day Price Move • Apr 10
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹1,714, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 126% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹1,268 per share. Reported Earnings • Feb 08
Third quarter 2025 earnings released: EPS: ₹18.28 (vs ₹15.44 in 3Q 2024) Third quarter 2025 results: EPS: ₹18.28 (up from ₹15.44 in 3Q 2024). Revenue: ₹4.93b (up 13% from 3Q 2024). Net income: ₹1.39b (up 19% from 3Q 2024). Profit margin: 28% (up from 27% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Jan 31
Caplin Point Laboratories Limited to Report Q3, 2025 Results on Feb 07, 2025 Caplin Point Laboratories Limited announced that they will report Q3, 2025 results on Feb 07, 2025 Tillkännagivande • Jan 07
Caplin Point Laboratories Ltd. Receives Establishment Inspection Report from the U.S. Food and Drug Administration Caplin Point Laboratories Ltd. announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the recent inspection conducted at Caplin Steriles' injectable and ophthalmic manufacturing facility located at Gummidipoondi. The unannounced USFDA inspection was conducted between August 5th and 9th, 2024 and was concluded with Zero 483 observations, reflecting the company's commitment to maintaining the higher standards of quality and compliance. This follows the intimation made to the Stock Exchanges on August 9th, 2024 immediately upon completion of the inspection about its outcome. The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements. Tillkännagivande • Nov 08
Caplin Point Laboratories Limited Announces Cessation of D Sathyanarayanan as an Independent Director Caplin Point Laboratories Limited announced that Mr. D Sathyanarayanan's term as an Independent Director of the Company had ceased with effect from the close of business hours of November 08, 2024 in accordance with the terms of his appointment and as he had served the maximum tenure permitted for an Independent Director. Reported Earnings • Nov 08
Second quarter 2025 earnings released: EPS: ₹17.22 (vs ₹15.13 in 2Q 2024) Second quarter 2025 results: EPS: ₹17.22 (up from ₹15.13 in 2Q 2024). Revenue: ₹5.04b (up 23% from 2Q 2024). Net income: ₹1.31b (up 14% from 2Q 2024). Profit margin: 26% (down from 28% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Oct 31
Caplin Point Laboratories Limited to Report Q2, 2025 Results on Nov 07, 2024 Caplin Point Laboratories Limited announced that they will report Q2, 2025 results on Nov 07, 2024 Price Target Changed • Oct 11
Price target increased by 14% to ₹2,142 Up from ₹1,883, the current price target is an average from 3 analysts. New target price is 12% above last closing price of ₹1,906. Stock is up 72% over the past year. The company is forecast to post earnings per share of ₹67.78 for next year compared to ₹60.19 last year. Upcoming Dividend • Sep 16
Upcoming dividend of ₹2.50 per share Eligible shareholders must have bought the stock before 23 September 2024. Payment date: 30 October 2024. Payout ratio is a comfortable 8.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.0%). Lower than average of industry peers (0.6%). New Risk • Sep 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Sep 05
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹2,120, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 130% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹871 per share. Valuation Update With 7 Day Price Move • Aug 19
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹1,846, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 166% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹871 per share. Price Target Changed • Aug 09
Price target increased by 17% to ₹1,717 Up from ₹1,472, the current price target is an average from 3 analysts. New target price is 14% above last closing price of ₹1,501. Stock is up 45% over the past year. The company is forecast to post earnings per share of ₹64.00 for next year compared to ₹60.19 last year. Declared Dividend • Aug 09
Dividend of ₹2.50 announced Dividend of ₹2.50 is the same as last year. Ex-date: 23rd September 2024 Payment date: 30th October 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (9% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased by an average of 26% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 11% over the next year, which should provide support to the dividend and adequate earnings cover. Tillkännagivande • Aug 08
Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024 Caplin Point Laboratories Limited at its board meeting held on August 7, 2024, recommended a Final Dividend of INR 2.5 (125%) per equity share of INR 2 each for the financial year ended March 31, 2024. This shall be paid subject To Approve the shareholders at the upcoming Annual General Meeting. Reported Earnings • Aug 08
First quarter 2025 earnings released: EPS: ₹16.32 (vs ₹13.62 in 1Q 2024) First quarter 2025 results: EPS: ₹16.32 (up from ₹13.62 in 1Q 2024). Revenue: ₹4.78b (up 21% from 1Q 2024). Net income: ₹1.24b (up 20% from 1Q 2024). Profit margin: 26% (in line with 1Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year and the company’s share price has also increased by 20% per year. Tillkännagivande • Aug 07
Caplin Point Laboratories Limited, Annual General Meeting, Sep 30, 2024 Caplin Point Laboratories Limited, Annual General Meeting, Sep 30, 2024. Tillkännagivande • Jul 31
Caplin Point Laboratories Limited to Report Q1, 2025 Results on Aug 07, 2024 Caplin Point Laboratories Limited announced that they will report Q1, 2025 results on Aug 07, 2024 Tillkännagivande • Jun 13
Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer Caplin Point Laboratories Limited announced the appointment of Mr. Thiagaraja Manikandan as Chief Transformation & Digital Officer with effect from June 11, 2024. He will be responsible for overseeing the Company's digital initiatives. Term: Full-time employment. With over three decades of leadership experience, Mr. Thiagaraja Manikandan has spearheaded digital transformations in a wide spectrum of industries, spanning from food and agribusiness to manufacturing, retail, CPG, global logistics, direct marketing consumer durables, and media. He is expert in both B2B and B2C business environments. Valuation Update With 7 Day Price Move • Jun 11
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹1,459, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 118% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹979 per share. Reported Earnings • May 18
Full year 2024 earnings: Revenues in line with analyst expectations Full year 2024 results: Revenue: ₹17.6b (up 20% from FY 2023). Net income: ₹4.57b (up 22% from FY 2023). Profit margin: 26% (in line with FY 2023). Revenue was in line with analyst estimates. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Tillkännagivande • May 17
Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024 Caplin Point Laboratories Limited announced that at its board meeting held on May 16, 2024, declared an interim dividend of INR. 2.5 (125%) per equity share of face value of INR 2 each for the financial year ended March 31, 2024. Fixed May 31,2024 as record date for determining the eligibility of the shareholders for the purpose of interim dividend. Tillkännagivande • May 11
Caplin Point Laboratories Limited to Report Fiscal Year 2024 Results on May 16, 2024 Caplin Point Laboratories Limited announced that they will report fiscal year 2024 results at 12:15 PM, Indian Standard Time on May 16, 2024 Reported Earnings • Feb 10
Third quarter 2024 earnings released: EPS: ₹15.44 (vs ₹12.86 in 3Q 2023) Third quarter 2024 results: EPS: ₹15.44 (up from ₹12.86 in 3Q 2023). Revenue: ₹4.53b (up 22% from 3Q 2023). Net income: ₹1.17b (up 20% from 3Q 2023). Profit margin: 26% (in line with 3Q 2023). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Jan 31
Caplin Point Laboratories Limited to Report Q3, 2024 Results on Feb 09, 2024 Caplin Point Laboratories Limited announced that they will report Q3, 2024 results on Feb 09, 2024 Valuation Update With 7 Day Price Move • Nov 16
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,285, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 174% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹696 per share. Price Target Changed • Nov 13
Price target increased by 8.0% to ₹1,076 Up from ₹996, the current price target is an average from 3 analysts. New target price is 17% below last closing price of ₹1,293. Stock is up 67% over the past year. The company is forecast to post earnings per share of ₹59.70 for next year compared to ₹49.62 last year. Reported Earnings • Nov 10
Second quarter 2024 earnings released: EPS: ₹15.13 (vs ₹12.09 in 2Q 2023) Second quarter 2024 results: EPS: ₹15.13 (up from ₹12.09 in 2Q 2023). Revenue: ₹4.30b (up 20% from 2Q 2023). Net income: ₹1.15b (up 25% from 2Q 2023). Profit margin: 27% (up from 26% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Nov 02
Caplin Point Laboratories Limited to Report Q2, 2024 Results on Nov 09, 2023 Caplin Point Laboratories Limited announced that they will report Q2, 2024 results on Nov 09, 2023 Tillkännagivande • Sep 23
Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023 Caplin Point Laboratories Limited at the AGM held on September 21, 2023 approved to declare final dividend of INR 2.5 (125%) per equity share of INR 2 as recommended by the Board of Directors of the company and to ratify the Interim Dividend of INR 2 (10 %) per equity share of INR 2 aggregating to INR 4.5 (225%) for the year ended March 31,2023. Upcoming Dividend • Sep 07
Upcoming dividend of ₹2.50 per share at 0.5% yield Eligible shareholders must have bought the stock before 14 September 2023. Payment date: 21 October 2023. Payout ratio is a comfortable 9.1% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.9%). Tillkännagivande • Aug 31
Caplin Point Laboratories Limited, Annual General Meeting, Sep 21, 2023 Caplin Point Laboratories Limited, Annual General Meeting, Sep 21, 2023, at 10:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the year ended March 31, 2023 along with the Reports of the Board of Director's and the Auditor's thereon; to consider declaration of Final Dividend and ratification of Interim Dividend; to re-appoint Mr. C. C. Paarthipan who retires by rotation, and being eligible, offers himself for re-appointment; and to consider other matters. Valuation Update With 7 Day Price Move • Aug 14
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹1,032, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 94% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹579 per share. Tillkännagivande • Aug 09
Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023 Caplin Point Laboratories Limited at its board meeting held on August 7, 2023, Recommended a Final Dividend of INR. 2.5 (125%) per equity share of INR 2 each for the financial year ended March 31, 2023. This shall be subject to approval of the shareholders at the forthcoming Annual General Meeting. Reported Earnings • Aug 08
First quarter 2024 earnings released: EPS: ₹13.62 (vs ₹11.21 in 1Q 2023) First quarter 2024 results: EPS: ₹13.62 (up from ₹11.21 in 1Q 2023). Revenue: ₹3.95b (up 14% from 1Q 2023). Net income: ₹1.03b (up 22% from 1Q 2023). Profit margin: 26% (up from 25% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 23% per year. Tillkännagivande • Aug 01
Caplin Point Laboratories Limited to Report Q1, 2024 Results on Aug 07, 2023 Caplin Point Laboratories Limited announced that they will report Q1, 2024 results on Aug 07, 2023 Tillkännagivande • Jun 13
Caplin Steriles Limited Gets United States Food and Drug Administration Approval for Cisatracurium Besylate Injection USP Caplin Steriles Limited has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Cisatracurium Besylate Injection USP, 10 mg/5 mL (2 mg/mL) and 200 mg/20 mL (10 mg/mL) Single-dose Vials; and 20 mg/10 mL (2 mg/mL). Multiple-dose Vials (Preserved)., a generic therapeutic equivalent version of (RLD), NIMBEX injection of AbbVie Inc. Cisatracurium besylate Injection USP is a nondepolarizing skeletal neuromuscular blocker, indicated as an adjunct to general anesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgical procedures. According to IQVIATM (IMS Health), Cisatracuriumesylate Injection USP had US sales of approximately $35 million for the 12-month period ending December 2022. Upcoming Dividend • Jun 02
Upcoming dividend of ₹2.00 per share at 0.3% yield Eligible shareholders must have bought the stock before 09 June 2023. Payment date: 26 August 2023. Payout ratio is a comfortable 4.0% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (1.0%). Reported Earnings • May 30
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: ₹49.62 (up from ₹39.61 in FY 2022). Revenue: ₹15.2b (up 20% from FY 2022). Net income: ₹3.76b (up 26% from FY 2022). Profit margin: 25% (up from 24% in FY 2022). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • May 14
Caplin Point Laboratories Limited to Report Q4, 2023 Results on May 24, 2023 Caplin Point Laboratories Limited announced that they will report Q4, 2023 results on May 24, 2023 Buying Opportunity • Mar 24
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 15%. The fair value is estimated to be ₹750, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 18%. Revenue is forecast to grow by 28% in 2 years. Earnings is forecast to grow by 14% in the next 2 years. Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: ₹12.86 (vs ₹9.90 in 3Q 2022) Third quarter 2023 results: EPS: ₹12.86 (up from ₹9.90 in 3Q 2022). Revenue: ₹3.86b (up 18% from 3Q 2022). Net income: ₹974.8m (up 30% from 3Q 2022). Profit margin: 25% (up from 23% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Jan 29
Caplin Point Laboratories Limited to Report Q3, 2023 Results on Feb 11, 2023 Caplin Point Laboratories Limited announced that they will report Q3, 2023 results on Feb 11, 2023 Price Target Changed • Nov 16
Price target increased to ₹948 Up from ₹678, the current price target is an average from 3 analysts. New target price is 26% above last closing price of ₹751. Stock is down 13% over the past year. The company is forecast to post earnings per share of ₹44.30 for next year compared to ₹39.61 last year. Reported Earnings • Nov 13
Second quarter 2023 earnings released: EPS: ₹12.09 (vs ₹9.91 in 2Q 2022) Second quarter 2023 results: EPS: ₹12.09 (up from ₹9.91 in 2Q 2022). Revenue: ₹3.76b (up 24% from 2Q 2022). Net income: ₹916.7m (up 22% from 2Q 2022). Profit margin: 24% (in line with 2Q 2022). Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Sep 14
Upcoming dividend of ₹2.00 per share Eligible shareholders must have bought the stock before 21 September 2022. Payment date: 29 October 2022. Payout ratio is a comfortable 9.7% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (1.0%). Reported Earnings • Aug 06
First quarter 2023 earnings released: EPS: ₹11.21 (vs ₹9.37 in 1Q 2022) First quarter 2023 results: EPS: ₹11.21 (up from ₹9.37 in 1Q 2022). Revenue: ₹3.60b (up 20% from 1Q 2022). Net income: ₹849.9m (up 20% from 1Q 2022). Profit margin: 24% (in line with 1Q 2022). Over the next year, revenue is forecast to grow 16%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 19
Investor sentiment improved over the past week After last week's 21% share price gain to ₹801, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 113% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹375 per share. Upcoming Dividend • May 16
Upcoming dividend of ₹2.00 per share Eligible shareholders must have bought the stock before 23 May 2022. Payment date: 11 June 2022. Payout ratio is a comfortable 8.8% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (1.0%). Reported Earnings • May 15
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Full year 2022 results: EPS: ₹39.61 (up from ₹32.03 in FY 2021). Net income: ₹3.00b (up 24% from FY 2021). Post-clinical trial products Approved (during full year): 1 Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Additional Non-Executive Independent Director Chanderkanta Gariyali was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 04
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹9.90 (up from ₹8.52 in 3Q 2021). Revenue: ₹3.36b (up 22% from 3Q 2021). Net income: ₹749.5m (up 16% from 3Q 2021). Profit margin: 22% (down from 24% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the next year, revenue is forecast to grow 12%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Dec 06
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Additional Non-Executive Independent Director Chanderkanta Gariyali was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 
